Research
Hormonal
Pharmacotherapy (e.g., Orlistat) is recommended as an adjunct to lifestyle intervention for patients with BMI >25 (or >23 with comorbidities) who fail to achieve initial goals, but must be discontinued if <5-10% weight loss is achieved after 3 months.
If lifestyle changes alone aren't enough, ask your doctor about Orlistat. It blocks fat absorption. However, it only works if you stick to your diet. If you don't lose at least 5-10% of your weight in 3 months, stop the drug—it's not working for you.
GoodConditionalHIGH confidence
Pharmacotherapy is recommended as an adjunct to comprehensive lifestyle intervention... If the patient continues to be unresponsive (less than 5% to 10% weight loss of baseline weight for 3 months)... the clinician should consider discontinuing the treatment.
Why this rating
Guideline based on FDA approvals and clinical trials.
Source
2014 Clinical Practice Guidelines for Overweight and Obesity in Korea
Mee Kyoung Kim et al. · Endocrinology and Metabolism · 2014
DOI 10.3803/enm.2014.29.4.405
clinical_guidelineCited 321×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Korean adults should be diagnosed with obesity at a BMI ≥25 kg/m², which is lower than the standard Western cutoff of 30 kg/m², due to higher body fat percentage and increased mortality risk at lower BMIs in Asian populations.Good
- Initial weight loss goal of 5-10% within 6 months via caloric restriction (1200-1500 kcal/day for women, 1500-1800 kcal/day for men) and moderate aerobic/resistance exercise is the standard lifestyle intervention for obesity management.Good
- Bariatric surgery is an appropriate option for Asian adults with BMI >35 kg/m² (with or without comorbidities) or >40 kg/m² (without comorbidities) who fail behavioral treatment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →